Eurydice Angeli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eurydice Angeli has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Guilhem Bousquet
Université Sorbonne Paris Nord
3 shared publications Laetitia Marisa
Multi-site Medical Biology Laboratory SeqOIA, Paris F-75000, France
2 shared publicationsMichael Soussan
Nuclear Medicine Departments, AP-HP-Hôpital Avicenne, Bobigny F-93000, France; Université Sorbonne Paris Nord, Villetaneuse F-93439, France
2 shared publicationsAlexander Ariel Padrón González
INSERM, UMR_S942 MASCOT, F-75006, Paris, France
1 shared publicationAmal Ait-Omar
Genetic Unit, AP-HP-Hôpital Avicenne, Bobigny F-93000, France
1 shared publication- Ana Fortuna
Unidade Local de Saúde do Algarve, Portugal
1 shared publication
Latest Publications
- Open Access
- 11 June 2026
- Published by Elsevier in The Breast
- Vol. 88, 104838
De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study
- 11 June 2026
- Published by Elsevier in The Breast
- Vol. 88, 104838
Open AccessDe-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study
- Open Access
- 30 April 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 199, 119402
Integrative and interactive genomic analyses guiding personalized combined therapy improve clinical benefit in metastatic patients: A monocentric real-life experience
- 30 April 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 199, 119402
Open AccessIntegrative and interactive genomic analyses guiding personalized combined therapy improve clinical benefit in metastatic patients: A monocentric real-life experience
- Open Access
- 10 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 3590
HER2 Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review
Anti-HER2 therapies have dramatically improved the prognosis of human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. However, the correlation between the HER2 copy number and the response rate to anti-HER2 remains unclear. Here, following the PRISMA method, we performed a meta-analysis in the neoadjuvant setting in breast cancer to study the association between the HER2 amplification level and the pathological complete response (pCR) to anti-HER2 therapies. Nine articles (four clinical trials, five observational studies) were retrieved after full-text screening, involving 11,238 women with locally advanced breast cancer in the neoadjuvant setting. The median HER2/CEP17 ratio cut-off value was 5.0 ± 5.0 (min-max = 1.0–14.0). For the overall population, the median pCR rate was 48% using the random effect model. The studies were categorized in quartiles as follows: ≤2 (Class 1); 2.1 to 5.0 (Class 2); 5.1 to 7.0 (Class 3); and >7.0 (Class 4). After grouping, the pCR rates were 33%, 49%, 57%, and 79%, respectively. When we excluded the study by Greenwell et al., which accounted for 90% of the patients, using the same quartiles, we still observed an increasing rate of pCR as the HER2/CEP17 ratio increased. This is the first meta-analysis demonstrating the relationship between the HER2 amplification level and the percentage of pCR in the neoadjuvant setting among women with HER2-overexpressing breast cancer, with potential therapeutic applications.
- 10 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 3590
Open AccessHER2 Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review
Anti-HER2 therapies have dramatically improved the prognosis of human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. However, the correlation between the HER2 copy number and the response rate to anti-HER2 remains unclear. Here, following the PRISMA method, we performed a meta-analysis in the neoadjuvant setting in breast cancer to study the association between the HER2 amplification level and the pathological complete response (pCR) to anti-HER2 therapies. Nine articles (four clinical trials, five observational studies) were retrieved after full-text screening, involving 11,238 women with locally advanced breast cancer in the neoadjuvant setting. The median HER2/CEP17 ratio cut-off value was 5.0 ± 5.0 (min-max = 1.0–14.0). For the overall population, the median pCR rate was 48% using the random effect model. The studies were categorized in quartiles as follows: ≤2 (Class 1); 2.1 to 5.0 (Class 2); 5.1 to 7.0 (Class 3); and >7.0 (Class 4). After grouping, the pCR rates were 33%, 49%, 57%, and 79%, respectively. When we excluded the study by Greenwell et al., which accounted for 90% of the patients, using the same quartiles, we still observed an increasing rate of pCR as the HER2/CEP17 ratio increased. This is the first meta-analysis demonstrating the relationship between the HER2 amplification level and the percentage of pCR in the neoadjuvant setting among women with HER2-overexpressing breast cancer, with potential therapeutic applications.
- Open Access
- 1 February 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 7 (7) , e2200582
Olaparib in the Setting of Radiotherapy-Associated Sarcoma: What Can Precision Medicine Offer For Rare Cancers?
- 1 February 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 7 (7) , e2200582
Open AccessOlaparib in the Setting of Radiotherapy-Associated Sarcoma: What Can Precision Medicine Offer For Rare Cancers?
- 19 October 2022
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 82 (5) , 719-720
Pyrogenic lower limbs
- 19 October 2022
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 82 (5) , 719-720
Pyrogenic lower limbs